Phase III follow up data on Imbruvica (ibrutinib) shows efficacy in chronic lymphocytic leukemia and small lymphocytic lymphoma- AbbVie
AbbVie has announced longer-term follow-up results from Phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Findings include an analysis of outcomes from the RESONATE (PCYC-1112) and RESONATE-2 (PCYC-1115) trials, which showed Imbruvica was associated with favorable progression-free survival (PFS) and overall survival (OS) regardless of line of therapy (previously treated or treatment-na�ve; abstract 7520).
An analysis of the RESONATE and RESONATE-2 trials showed Imbruvica was associated with favorable PFS and OS outcomes, as well as a high overall response rate (ORR) in previously treated and treatment-na�ve patients with CLL/SLL, regardless of line of therapy. The median PFS and OS were not reached in treatment-na�ve or previously-treated patients; 89-92% of patients treated with ibrutinib at first or second line of therapy remained progression-free at two years. Additionally, ORR was high in both previously treated and treatment-na�ve patients (92% and 91%, respectively).
The safety profile was similar for both patient groups1 and was consistent with previously-reported outcomes. Data from the RESONATE and RESONATE-2 studies served as the basis for the 2014 and 2016 FDA approvals of Imbruvica for patients with CLL/SLL. The most commonly occurring adverse reactions (more than 20%) in studies that supported the FDA approvals for patients with CLL/SLL were neutropenia, thrombocytopenia, anemia, diarrhea, musculoskeletal pain, nausea, rash, bruising, fatigue, pyrexia and hemorrhage.
Related news and insights
Scynexis, Inc. announced that the FDA has approved a second indication for Bexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outco me analysis in the Phase III TRAILBLAZER-ALZ 4 study , providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies